Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
113 participants
INTERVENTIONAL
2015-02-28
2019-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The investigators will determine whether:
* clinical screening outcomes are more favorable in the group of trained physicians compared to non trained physicians
* there is an increase of knowledge about skin cancer screening among trained physicians, compared to non trained physicians
* skin cancer screenings are associated with psycho-social harms
* population-based screening has an effect on the overall incidence and stage-specific-incidence of skin cancer in Alberta
The investigators are aiming to recruit 100 physicians per region (total of 200 physicians) who will screen 40,000 to 80,000 individuals over a period of 20 months.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Risk Information and Skin-cancer Education for Undergraduate Prevention
NCT03979872
Predictors of Patient Attitudes and Barriers to Skin Cancer Screening
NCT02235116
Differential Risks for Melanoma: p16 and DNA Repair
NCT00615095
Using MC1R Genotype to Impact Melanoma Risk Behavior
NCT03509467
Dermoscopy and Histopathology in Non-melanocytic Skin Tumors
NCT06523816
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
SCREENING
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Skin Cancer Screening Training
Recruited family physicians and dermatologists in Calgary, Canada, take part in a 5.5-hour face-to-face skin cancer screening training program. Screening for skin cancer will be conducted by trained physicians according to instructions they received in the training program.
Skin Cancer Screening Training
Topics of the 5.5-hour in-class course include: the screening test, types of skin cancer (signs and symptoms), case history taking, epidemiology of skin cancer, etiology, risk factors and risk groups, communicative aspects of primary and secondary preventive measures, and benefits and harms of cancer screenings.
No Skin Cancer Screening Training
Recruited family physicians and dermatologists in Edmonton, Canada, WILL BE TRAINED AFTER THE SCREENING PHASE, i.e. during the screening phase non-trained physicians will carry out skin cancer screenings according to standard medical practice.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Skin Cancer Screening Training
Topics of the 5.5-hour in-class course include: the screening test, types of skin cancer (signs and symptoms), case history taking, epidemiology of skin cancer, etiology, risk factors and risk groups, communicative aspects of primary and secondary preventive measures, and benefits and harms of cancer screenings.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male and female residents of Alberta mainly living and receiving care in Edmonton or in Calgary
* Age 20+
* English-speaking
* Individuals who consent to participate
2. Physicians
* Registered dermatologists and family physicians administering care either in Edmonton or in Calgary
* English-speaking
* Physicians who consent to participate
Exclusion Criteria
20 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Calgary
OTHER
University of Alberta
OTHER
Association of Dermatological Prevention, Germany
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lynne H Robertson, MD, FRCPC
Role: PRINCIPAL_INVESTIGATOR
University of Calgary
Gordon E Searles, MD, FRCPC
Role: PRINCIPAL_INVESTIGATOR
University of Alberta
Eckhard W Breitbart, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Association of Dermatological Prevention, Germany
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Calgary, University of Alberta
Calgary, Edmonton, Alberta, Canada
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Study website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LEO-SCSES_1013
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.